These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

594 related articles for article (PubMed ID: 30665953)

  • 21. SGLT2 Inhibitors as a Therapeutic Option for Diabetic Nephropathy.
    Kawanami D; Matoba K; Takeda Y; Nagai Y; Akamine T; Yokota T; Sango K; Utsunomiya K
    Int J Mol Sci; 2017 May; 18(5):. PubMed ID: 28524098
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Use of sodium-glucose co-transporter-2 inhibitors in Asian patients with type 2 diabetes and kidney disease: An Asian perspective and expert recommendations.
    Khoo CM; Deerochanawong C; Chan SP; Matawaran B; Sheu WH; Chan J; Mithal A; Luk A; Suastika K; Yoon KH; Ji L; Man NH; Pollock C
    Diabetes Obes Metab; 2021 Feb; 23(2):299-317. PubMed ID: 33155749
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Emerging roles of Sodium-glucose cotransporter 2 inhibitors in Diabetic kidney disease.
    Gan T; Song Y; Guo F; Qin G
    Mol Biol Rep; 2022 Nov; 49(11):10915-10924. PubMed ID: 36002651
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sodium Glucose Cotransporter-2 Inhibition and Cardiorenal Protection: JACC Review Topic of the Week.
    Cherney DZ; Odutayo A; Aronson R; Ezekowitz J; Parker JD
    J Am Coll Cardiol; 2019 Nov; 74(20):2511-2524. PubMed ID: 31727290
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sodium glucose cotransporter (SGLT)-2 inhibitors: Do we need them for glucose-lowering, for cardiorenal protection or both?
    Scholtes RA; van Baar MJB; Lytvyn Y; Bjornstad P; Nieuwdorp M; Cherney DZI; van Raalte DH
    Diabetes Obes Metab; 2019 Apr; 21 Suppl 2(Suppl 2):24-33. PubMed ID: 30843294
    [TBL] [Abstract][Full Text] [Related]  

  • 26. New Diabetes Therapies and Diabetic Kidney Disease Progression: the Role of SGLT-2 Inhibitors.
    Dekkers CCJ; Gansevoort RT; Heerspink HJL
    Curr Diab Rep; 2018 Mar; 18(5):27. PubMed ID: 29589183
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nonproteinuric progressive diabetic kidney disease.
    Zoccali C; Mallamaci F
    Curr Opin Nephrol Hypertens; 2019 May; 28(3):227-232. PubMed ID: 30672815
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibition of sodium-glucose cotransporter 2 to slow the progression of chronic kidney disease.
    Oguz F; Demoulin N; Thissen JP; Jadoul M; Morelle J
    Acta Clin Belg; 2022 Aug; 77(4):805-814. PubMed ID: 34404335
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sodium-Glucose Cotransporter-2 Inhibitors-Miracle Drugs for the Treatment of Chronic Kidney Disease Irrespective of the Diabetes Status: Lessons from the Dedicated Kidney Disease-Focused CREDENCE and DAPA-CKD Trials.
    Gohda T; Murakoshi M
    Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430228
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cardiorenal protection with SGLT2: Lessons from the cardiovascular outcome trials.
    Silva-Cardoso J; Sheikh O; Nashawi M; Pham S; Gallegos KM; Dinkha LR; Chilton RJ
    J Diabetes; 2020 Apr; 12(4):279-293. PubMed ID: 31688975
    [TBL] [Abstract][Full Text] [Related]  

  • 31. SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease.
    Zou H; Zhou B; Xu G
    Cardiovasc Diabetol; 2017 May; 16(1):65. PubMed ID: 28511711
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The sodium-glucose cotransporter 2 inhibitor tofogliflozin prevents diabetic kidney disease progression in type 2 diabetic mice.
    Li Z; Murakoshi M; Ichikawa S; Koshida T; Adachi E; Suzuki C; Ueda S; Gohda T; Suzuki Y
    FEBS Open Bio; 2020 Dec; 10(12):2761-2770. PubMed ID: 33098615
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cardiovascular outcomes of sodium-glucose cotransporter 2 inhibitors: A comprehensive review of clinical and preclinical studies.
    Ghosh RK; Bandyopadhyay D; Hajra A; Biswas M; Gupta A
    Int J Cardiol; 2016 Jun; 212():29-36. PubMed ID: 27017118
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis.
    Wu JH; Foote C; Blomster J; Toyama T; Perkovic V; Sundström J; Neal B
    Lancet Diabetes Endocrinol; 2016 May; 4(5):411-9. PubMed ID: 27009625
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effect of SGLT-2 inhibitors on albuminuria and proteinuria in diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials.
    Piperidou A; Sarafidis P; Boutou A; Thomopoulos C; Loutradis C; Alexandrou ME; Tsapas A; Karagiannis A
    J Hypertens; 2019 Jul; 37(7):1334-1343. PubMed ID: 31145707
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Role for Sodium-Glucose Cotransporter 2 Inhibitors in the Treatment of Chronic Kidney Disease: A Mini Review.
    Song J; Li X; Ni J
    Kidney Blood Press Res; 2023; 48(1):599-610. PubMed ID: 37717569
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mechanisms for Cardiorenal Protection of SGLT-2 Inhibitors.
    Georgianos PI; Vaios V; Dounousi E; Salmas M; Eleftheriadis T; Liakopoulos V
    Curr Pharm Des; 2021; 27(8):1043-1050. PubMed ID: 33463454
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Renoprotective Mechanism of Sodium-Glucose Cotransporter 2 Inhibitors: Focusing on Renal Hemodynamics.
    Kim NH; Kim NH
    Diabetes Metab J; 2022 Jul; 46(4):543-551. PubMed ID: 35929172
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Therapeutic Targeting of SGLT2: A New Era in the Treatment of Diabetes and Diabetic Kidney Disease.
    Shaffner J; Chen B; Malhotra DK; Dworkin LD; Gong R
    Front Endocrinol (Lausanne); 2021; 12():749010. PubMed ID: 34790170
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Effect of Sodium-Glucose Co-transporter-2 (SGLT-2) Inhibitors on Cardiometabolic Profile; Beyond the Hypoglycaemic Action.
    Lioudaki E; Androulakis ES; Whyte M; Stylianou KG; Daphnis EK; Ganotakis ES
    Cardiovasc Drugs Ther; 2017 Apr; 31(2):215-225. PubMed ID: 28444472
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.